Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxpentifylline for erythropoietin-resistant anaemia in chronic kidney disease
ACTRN12608000199314Phase 4Completed
- Sponsor
- Australasian Kidney Trials Network
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of pentoxifylline in Erythropoietin hyporesponsiveness and chronic kidney disease (CKD), sponsored by Australasian Kidney Trials Network. Primary endpoint: Difference in erythropoietin resistance index. Started Jun 2009; status: completed.
02
Drugs
pentoxifylline
03
Conditions
Erythropoietin hyporesponsivenesschronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12608000199314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000199314.